The Added-value of Staging ¹⁸F-FDG PET/CT in the Prediction of Overall Survival in the Patients with Bladder Cancer.

IF 0.9 Q4 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Molecular Imaging and Radionuclide Therapy Pub Date : 2024-02-22 DOI:10.4274/mirt.galenos.2023.65002

Seda Gülbahar Ateş, Bedriye Büşra Demirel, Halil Başar, Gülin Uçmak

{"title":"The Added-value of Staging 18F-FDG PET/CT in the Prediction of Overall Survival in the Patients with Bladder Cancer.","authors":"Seda Gülbahar Ateş, Bedriye Büşra Demirel, Halil Başar, Gülin Uçmak","doi":"10.4274/mirt.galenos.2023.65002","DOIUrl":null,"url":null,"abstract":"Objectives: This retrospective study aimed to evaluate the prognostic importance of 18F-fluorodeoxyglucose (18F-FDG)-positive pelvic lymph nodes (LNs) and extra-pelvic disease on staging 18F-FDG positron emission tomography/computed tomography (PET/CT) in patients with bladder cancer.Methods: Bladder cancer patients who underwent staging 18F-FDG PET/CT were included in the study. Histopathologic features of tumors, therapy histories, presence of distinguishable tumors on CT and PET images, sizes and maximum standardized uptake value (SUVmax) of primary tumors, total numbers, sizes, and SUVmax of 18F-FDG-positive pelvic and extra-pelvic LNs, and total numbers and SUVmax of distant metastases (M1a/1b) were recorded. Patients were followed up until death or the last medical visit. Factors predicting overall survival were determined using Cox regression analysis.Results: Fifty-five patients [median age: 70 (53-84), 48 (87.3%) male, 7 (12.7%) female] with bladder cancer were included in this study. Twenty-nine (52.7%) patients had 18F-FDG positive pelvic LNs, while 24 (43.7%) patients had 18F-FDG positive extra-pelvic disease. Patients with 18F-FDGpositive pelvic LNs had a higher rate of extra-pelvic disease (p=0.003). The median follow-up duration was 13.5 months. The median overall survival was 16.3 months [95% confidence interval (CI) 8.9-23.7]. The primary tumor distinguishability on PET (p=0.011) and CT (p=0.009) images, the presence of 18F-FDG-positive pelvic LNs (p<0.001) and 18F-FDG-positive extra-pelvic disease/distant metastases (M1a/M1b) (p<0.001), and the number of distant metastases (p=0.034) were associated with mortality. The 18F-FDG-positive extra-pelvic disease/distant metastases [p=0.029, odds ratio: 4.15 (95% CI 1.16-14.86)] was found to be an independent predictor of mortality in patients with bladder cancer.Conclusion: The presence of 18F-FDG-positive extra-pelvic disease in pretreatment 18F-FDG PET/CT is an important prognostic factor in bladder cancer patients.","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":null,"pages":null},"PeriodicalIF":0.9000,"publicationDate":"2024-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10899737/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Imaging and Radionuclide Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4274/mirt.galenos.2023.65002","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: This retrospective study aimed to evaluate the prognostic importance of ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG)-positive pelvic lymph nodes (LNs) and extra-pelvic disease on staging ¹⁸F-FDG positron emission tomography/computed tomography (PET/CT) in patients with bladder cancer.

Methods: Bladder cancer patients who underwent staging ¹⁸F-FDG PET/CT were included in the study. Histopathologic features of tumors, therapy histories, presence of distinguishable tumors on CT and PET images, sizes and maximum standardized uptake value (SUV_max) of primary tumors, total numbers, sizes, and SUV_max of ¹⁸F-FDG-positive pelvic and extra-pelvic LNs, and total numbers and SUV_max of distant metastases (M1a/1b) were recorded. Patients were followed up until death or the last medical visit. Factors predicting overall survival were determined using Cox regression analysis.

Results: Fifty-five patients [median age: 70 (53-84), 48 (87.3%) male, 7 (12.7%) female] with bladder cancer were included in this study. Twenty-nine (52.7%) patients had ¹⁸F-FDG positive pelvic LNs, while 24 (43.7%) patients had ¹⁸F-FDG positive extra-pelvic disease. Patients with ¹⁸F-FDGpositive pelvic LNs had a higher rate of extra-pelvic disease (p=0.003). The median follow-up duration was 13.5 months. The median overall survival was 16.3 months [95% confidence interval (CI) 8.9-23.7]. The primary tumor distinguishability on PET (p=0.011) and CT (p=0.009) images, the presence of ¹⁸F-FDG-positive pelvic LNs (p<0.001) and ¹⁸F-FDG-positive extra-pelvic disease/distant metastases (M1a/M1b) (p<0.001), and the number of distant metastases (p=0.034) were associated with mortality. The ¹⁸F-FDG-positive extra-pelvic disease/distant metastases [p=0.029, odds ratio: 4.15 (95% CI 1.16-14.86)] was found to be an independent predictor of mortality in patients with bladder cancer.

Conclusion: The presence of ¹⁸F-FDG-positive extra-pelvic disease in pretreatment ¹⁸F-FDG PET/CT is an important prognostic factor in bladder cancer patients.

查看原文本刊更多论文

分期 18F-FDG PET/CT 在预测膀胱癌患者总生存期中的附加值

研究目的这项回顾性研究旨在评估18F-氟脱氧葡萄糖（18F-FDG）阳性盆腔淋巴结（LN）和盆腔外疾病对膀胱癌患者分期18F-FDG正电子发射断层扫描/计算机断层扫描（PET/CT）预后的重要性：研究对象包括接受分期 18F-FDG PET/CT 检查的膀胱癌患者。记录肿瘤的组织病理学特征、治疗史、CT 和 PET 图像上可分辨的肿瘤、原发肿瘤的大小和最大标准化摄取值（SUVmax）、18F-FDG 阳性盆腔和盆腔外 LN 的总数、大小和 SUVmax，以及远处转移灶（M1a/1b）的总数和 SUVmax。对患者进行随访，直至死亡或最后一次就诊。采用Cox回归分析确定预测总生存率的因素：本研究共纳入55名膀胱癌患者[中位年龄：70（53-84）岁，48（87.3%）名男性，7（12.7%）名女性]。29例（52.7%）患者的盆腔LN呈18F-FDG阳性，24例（43.7%）患者的盆腔外疾病呈18F-FDG阳性。18F-FDG 阳性盆腔 LN 患者的盆腔外疾病发生率更高（P=0.003）。中位随访时间为13.5个月。中位总生存期为 16.3 个月[95% 置信区间 (CI) 8.9-23.7]。PET（p=0.011）和CT（p=0.009）图像上的原发肿瘤可分辨性、18F-FDG阳性盆腔LN（p18F-FDG阳性盆腔外疾病/远处转移灶（M1a/M1b）（p18F-FDG阳性盆腔外疾病/远处转移灶 [p=0.029, odds ratio: 4.15 (95% CI 1.16-14.86)] 是膀胱癌患者死亡率的独立预测因素：结论：治疗前 18F-FDG PET/CT 中出现 18F-FDG 阳性的盆腔外疾病是膀胱癌患者的一个重要预后因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Molecular Imaging and Radionuclide Therapy RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING-

CiteScore

1.30

自引率

0.00%

发文量

期刊介绍： Molecular Imaging and Radionuclide Therapy (Mol Imaging Radionucl Ther, MIRT) is publishes original research articles, invited reviews, editorials, short communications, letters, consensus statements, guidelines and case reports with a literature review on the topic, in the field of molecular imaging, multimodality imaging, nuclear medicine, radionuclide therapy, radiopharmacy, medical physics, dosimetry and radiobiology.